ArticleFrontiers in oncology2026

Epcoritamab plus R² in follicular lymphoma: practice-changing efficacy meets unresolved toxicity trade-offs.

Qinghua Ke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.